MENU

Comparison of the Teratoma assay and in vitro surrogate tests for assessment of pluripotency of human pluripotent stem cells

Speaker
  • Co-Head, LUMC hiPSC Core Facility, Dept. of Anatomy & Embryology Leiden, University Medical Center
    Biography
      Christian Freund received his PhD at the Max Delbrück Centre for Molecular Medicine in Berlin, Germany, studying the role of transcription factor NF-kB in cardiac hypertrophy in mice. In 2006 he joined the lab of Christine Mummery at the Hubrecht Institute in Utrecht, The Netherlands. He initially worked on the differentiation of human embryonic stem cells into cardiomyocytes and showed that insulin had adverse effects on early specification into the mesoderm lineage. After having moved with the Mummery group to the Leiden University Medical Centre (LUMC) he started working on human cellular reprogramming by exogenous transcription factors. Since 2010 he has been co-heading the LUMC hiPSC core facility which up to date generated human induced pluripotent cells from more than 125 tissue samples for LUMC researchers and external investigators

    Abstract

    For optimal use of human induced pluripotent stem cells (hiPSCs) it is essential to identify lines that are fully reprogrammed and of high quality with proven pluripotency in terms of differentiation. The ability to form teratomas in vivo is regarded as functional evidence of pluripotency for human pluripotent stem cells (hPSCs). Since the Teratoma assay is animal-dependent, laborious and only qualitative, there is an ongoing debate whether it is an acceptable tool. This has led to the development of an assay for quantitative analysis of teratomas (TeratoScore) as well as in vitro alternatives such as PluriTest and the hPSC Scorecard. We compared normal hPSCs, hiPSCs with reactivated reprogramming transgenes and nullipotent human embryonal carcinoma (hEC) cells in these assays. Cells were cultured on Vitronectin in TESR-E8 media (hPSCs) or in DMEM/10% FCS (hEC cells). The quality of undifferentiated cells was analysed by FACS for OCT3/4 as well as karyotyping. As assessed by immunohistochemistry and immunofluorescent staining the normal hPSCs gave rise to typical teratomas whereas the xenografts of the hEC cells and the hiPSCs with the reactivated reprogramming transgenes were largely undifferentiated and displayed a malignant phenotype.

    TeratoScore confirmed typical teratomas and tumors lacking differentiation but was unable to identify partially differentiated tumors. The hPSC Scorecard assay confirmed the line-specific differentiation propensities in vitro. However, when undifferentiated cells were analysed with PluriTest only hEC cells were identified as distinct. All other undifferentiated cells lines including hiPSCs with reactivated transgenes were undistinguishable and resembled normal hPSCs. We propose a combination of PluriTest and hPSC Scorecard for quantitation of pluripotency status and function of hPSCs used for in vitro purposes. By contrast, the Teratoma assay is the only method which is able to determine whether hPSCs could potentially develop a malignant phenotype, resulting in exclusion for any clinical application.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    JUN 03, 2021 12:00 PM CST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    JUN 03, 2021 12:00 PM CST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 3, 2021 TIME: 12:00pm SGT This webinar is a virtual event that focuses on utilizing the Gibco CTS Rotea System for Cell and Gene Therapy...
    DEC 16, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 16, 2020 8:00 AM PST
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...

    Comparison of the Teratoma assay and in vitro surrogate tests for assessment of pluripotency of human pluripotent stem cells


    Specialty

    Cancer Research

    Cell Biology

    Geography

    North America100%

    Registration Source

    Website Visitors100%

    Job Title

    Facility/Department Manager100%

    Organization

    Life Science Company100%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more